University of Illinois, Urbana-Champaign
Division of University of Illinois
Latest From University of Illinois, Urbana-Champaign
The big pharma could not confirm whether AveXis co-founder and CSO Brian Kaspar and his brother, SVP of R&D Allan Kaspar, were fired. Instead, Novartis noted that the withholding of preclinical safety data for Zolgensma was limited to the action of a few employees. NIBR preclinical safety chief takes key role at AveXis
Emerging Company Profile: 1ST Biotherapeutics CEO highlights its lead candidate program – a novel small molecule c-Abl inhibitor, which touts superior blood-brain penetration and selectivity – for its potential to become a disease-modifying drug for Parkinson's disease.
More than 50% of drugs sold in the US are natural products, or derivatives of them, but drugmakers have long since tired of sifting, sorting, and attempting to synthesize the typically large and complex molecules that nature produces. Revolution Medicines Inc. aims to develop a platform that will break natural products into “building blocks” that medicinal chemists can then assemble and tweak in ways never before possible.
In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.